Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGYN trial: Gemcitabine vs Mitomycin as adjuvant therapy in intermediate-risk NMIBC
2020-001728-33Phase 3Active
- Sponsor
- Region Skåne
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-muscle-invasive bladder cancer (NMIBC) comparing Gemcitabine arm with Mitomycin arm (2 arms). Primary endpoint: Recurrence-free survival. Started Oct 2020; status: active.
02
Drugs
gemcitabinemitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2020-001728-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001728-33.